Remember your first success story with Seretide (salmeterol/fluticasone propionate)

Remember your first success story with Seretide (salmeterol/fluticasone propionate)

Seretide Inhalers
Save 50%

Seretide (salmeterol/fluticasone
propionate) Evohaler
25/250mcg £29.32

Save 33%

Seretide (salmeterol/fluticasone
propionate) Evohaler
25/125mcg £23.45

*List price change since August 2018

What is Seretide?

Asthma Indication1

Seretide is indicated in the regular treatment of asthma where use of a combination product (long- acting β2 agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist

Or

  • patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist

Dosing

The recommended dose of Seretide Evohaler 25/50mcg, 25/125mcg or 25/250mcg is two inhalations, twice daily.

Seretide Evohaler comes in three different doses allowing flexibility of dosing for your patient with asthma at low, medium and high dose inhaled steroid1.

Why should you prescribe Seretide?

1

Efficacy

75% of patients given Seretide achieved control and were still well controlled after 1 year.2 Patients should not need their rescue inhaler 6 days out of 7 (extrapolated from the GOAL study data)*3

2

Flexibility of 3 doses

Allowing patients to step up and
down as needed; providing
continuity of care and an individual
approach to managing asthma control1

3

Paediatric Licence

Seretide 25/50 mcg Evohaler is the only MDI licensed in paediatric asthma for children 4 years and upwards, which can be used with both the Volumatic and Aerochamber1

*GOAL Study Stratum 2 patients defined as those patients who were on 500 µg or less of beclomethasone propionate daily or equivalent. The GOAL data has been extrapolated from over one year into one week4.

Seretide comes in the Evohaler MDI

Seretide 25/50 mcg Evohaler is the only MDI licensed in paediatric asthma for children 4 years and upwards, which can be used with both the Volumatic and Aerochamber1.

How to use the Evohaler:

Save
versus
Fostair
£

Compared to Fostair5...

  • Seretide Evohaler 25/125mcg b.d. is over £5 cheaper than Fostair 100/6mcg b.d.6
  • Small particles in Fostair do not confer clinically relevant benefits over Seretide7
  • Seretide has a license for paediatric and adolescents under 18 years

Compared to Sirdupla8, Seretide...

  • Has a license for paediatric asthma
  • Is available in a low dose (25/50 mcg) inhaler
  • Can be used in patients with mild asthma
Greater
flexibility
versus
Sirdupla

Free resources to help you and your patients use Seretide Evohaler

Identify patients using the ACT score pad

The Asthma Control Test

Provides a numerical score that helps healthcare professionals and their patients determine if asthma symptoms are well controlled.

Order now
Ellipta inhalation trainer

Help demonstrate the
Evohaler device to patients

This Placebo Demonstration Device helps healthcare professionals show patients how to use the Evohaler device correctly.

Order now
Ellipta demonstration device

Teach patients to use the
Evohaler device

How to Use Patient Leaflet Pad to support patients to correctly use their Evohaler on its own and with a Volumatic Spacer.

Order now

Looking to review the effects of the 2018 price change in your Local Health Economy (LHE) or manage your rebate?

Value.GSK

For Commissioners and Payers


Go to Value.GSK

How has the Seretide list price change affected my LHE?

To review the estimated financial savings of the 2018 Seretide list price change for your LHE, please visit value.gsk.com

Seretide Rebate

If you have an active Seretide Rebate contract please log into our value.gsk.com site for more information about what the 2018 Seretide price changes mean to your LHE.

If you are not registered, and you are a NHS medicine manager, respiratory commissioner or in an equivalent role, you can register quickly and easily by visiting value.gsk.com

References

  1. Seretide Evohaler SPC (August 2019)
  2. Bateman ED et al. Am J Respir Crit Care MED 2004; 170:836-844
  3. Woodcock AA et al. Prim Care Respir J 2007; Page 159 Table 2
  4. Data on File: REF-33119 & REF-38428
  5. Fostair SPC (August 2019)
  6. DM&D, NHSBSA (Accessed August 2019)
  7. Papi A, et al. Allergy 2007;62(10):1182–1188 (REF-9092)
  8. Sirdupla SPC (August 2019)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Seretide is a registered trademark of the GlaxoSmithKline group of companies

A.K Last Updated September 2019 PM-GB-FPS-WCNT-190006